Literature DB >> 22290984

Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock.

Fabio Silvio Taccone1, Frédéric Cotton, Sandrine Roisin, Jean-Louis Vincent, Frédérique Jacobs.   

Abstract

A patient with septic shock due to extensively drug resistant (XDR) Pseudomonas aeruginosa was cured by optimizing the meropenem (MEM) regimen to obtain at least 40% of the time between two administrations in which drug levels were four times higher than the MIC of the pathogen. As the standard drug dose did not achieve these optimal concentrations, the MEM regimen was progressively increased up to 12 g/day (3 g every 6 h in a 3-h extended infusion), which eventually resulted in sepsis resolution. High MEM dosage may represent a valuable therapeutic option for infection due to multidrug-resistant (MDR) strains, and drug monitoring would allow rapid regimen adjustment in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290984      PMCID: PMC3318384          DOI: 10.1128/AAC.06389-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan; Jarurat Punyo
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Authors:  Thomas P Lodise; Ben Lomaestro; George L Drusano
Journal:  Clin Infect Dis       Date:  2007-01-02       Impact factor: 9.079

3.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

4.  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Authors:  Christine T Ong; Pamela R Tessier; Chonghua Li; Charles H Nightingale; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2006-08-23       Impact factor: 2.803

5.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 6.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Int J Antimicrob Agents       Date:  2007-02-16       Impact factor: 5.283

Review 7.  Pharmacokinetic issues for antibiotics in the critically ill patient.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

8.  Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.

Authors:  Leonardo Lorente; Alejandro Jiménez; Salome Palmero; Juan José Jiménez; José Luís Iribarren; Melitón Santana; María M Martín; Maria L Mora
Journal:  Clin Ther       Date:  2007-11       Impact factor: 3.393

9.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

10.  Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.

Authors:  Sang-Ho Choi; Jung Eun Lee; Su Jin Park; Seong-Ho Choi; Sang-Oh Lee; Jin-Yong Jeong; Mi-Na Kim; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

View more
  25 in total

1.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

2.  Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Xingchen Bian; Xiaofen Liu; Yuancheng Chen; Daijie Chen; Jian Li; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Should Prolonged Infusion of β-Lactams Become Standard of Practice?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2017 Mar-Apr

4.  Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.

Authors:  S J Kaiser; N T Mutters; A DeRosa; C Ewers; U Frank; F Günther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-12       Impact factor: 3.267

Review 5.  Emergence of antibiotic-resistant extremophiles (AREs).

Authors:  Prashant Gabani; Dhan Prakash; Om V Singh
Journal:  Extremophiles       Date:  2012-08-21       Impact factor: 2.395

6.  Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.

Authors:  Jan J De Waele; S Carrette; M Carlier; V Stove; J Boelens; G Claeys; I Leroux-Roels; E Hoste; P Depuydt; J Decruyenaere; A G Verstraete
Journal:  Intensive Care Med       Date:  2013-12-20       Impact factor: 17.440

Review 7.  Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Petros I Rafailidis; Anastasios Kapaskelis; Konstantinos Z Vardakas
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

8.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27

9.  Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji
Journal:  Clin Microbiol Infect       Date:  2020-02-12       Impact factor: 8.067

Review 10.  Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions.

Authors:  L E B Nabarro; B Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.